DTE Energy Company (DTE)
NYSE: DTE · Real-Time Price · USD
140.26
+0.05 (0.04%)
Aug 8, 2025, 4:00 PM - Market closed
Marinus Pharmaceuticals Stock Forecast
Stock Price Forecast
The 14 analysts that cover Marinus Pharmaceuticals stock have a consensus rating of "Buy" and an average price target of $140.71, which forecasts a 0.32% increase in the stock price over the next year. The lowest target is $121 and the highest is $154.
Price Target: $140.71 (+0.32%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Marinus Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 4 | 4 | 4 | 4 | 4 |
| Buy | 6 | 6 | 5 | 6 | 6 | 6 |
| Hold | 5 | 4 | 4 | 4 | 4 | 5 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 14 | 14 | 13 | 14 | 14 | 15 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Barclays | Barclays | Hold Maintains $136 → $138 | Hold | Maintains | $136 → $138 | -1.61% | Jul 15, 2025 |
| JP Morgan | JP Morgan | Hold Maintains $145 → $147 | Hold | Maintains | $145 → $147 | +4.81% | Jul 15, 2025 |
| Barclays | Barclays | Hold Maintains $137 → $136 | Hold | Maintains | $137 → $136 | -3.04% | Jul 10, 2025 |
| Citigroup | Citigroup | Strong Buy Maintains $142 → $151 | Strong Buy | Maintains | $142 → $151 | +7.66% | May 23, 2025 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $136 → $134 | Buy | Maintains | $136 → $134 | -4.46% | May 22, 2025 |
Financial Forecast
Revenue This Year
13.54B
from 12.46B
Increased by 8.69%
Revenue Next Year
13.89B
from 13.54B
Increased by 2.59%
EPS This Year
7.28
from 6.77
Increased by 7.61%
EPS Next Year
7.81
from 7.28
Increased by 7.28%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 16.2B | 16.7B | 17.2B | ||
| Avg | 13.5B | 13.9B | 14.4B | ||
| Low | 12.0B | 10.7B | 10.9B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 29.7% | 23.3% | 24.1% | ||
| Avg | 8.7% | 2.6% | 3.8% | ||
| Low | -3.8% | -20.9% | -21.7% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 7.60 | 8.19 | 8.82 | ||
| Avg | 7.28 | 7.81 | 8.41 | ||
| Low | 6.99 | 7.45 | 7.99 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 12.3% | 12.5% | 12.9% | ||
| Avg | 7.6% | 7.3% | 7.7% | ||
| Low | 3.2% | 2.3% | 2.2% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.